Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last week:

‍Blogs :

Comparing Treatment Options: Luspatercept vs. Erythropoiesis-Stimulating Agents (ESAs)

Clinical Benefits of Luspatercept Dose Titration: Evidence from Real-World Data

MCH Minute Unavailable

Approaches to Starting and Adjusting Luspatercept Dosing

Imetelstat Sustains Transfusion Independence in Low-Risk MDS
‍
‍Also at MCH the News and Tweets never stop flowing!

Join Us at www.mycancerhaven.org

‍The Team @ MCH

Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.